Navigation Links
Maven Biotechnologies Receives $1.96 Million From the National Institutes of Health (NIH) to Develop Their LFIRE™ Label-Free Detection Technology for Proteomics
Date:10/1/2010

PASADENA, Calif., Oct. 1 /PRNewswire/ -- Maven Biotechnologies today announced that the company has been awarded $1.96 million by the National Institute for Allergy and Infectious Disease (NIAID), part of the NIH, to support the commercialization of their LFIRETM imaging technology for label-free protein microarrays and cell-based assays. The highly competitive grant was awarded to Maven through the federal stimulus package initiative for Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies (BRDG-SPAN).

(Logo: http://photos.prnewswire.com/prnh/20101001/LA75512LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20101001/LA75512LOGO)

"Maven welcomes the support of the NIH to bring our platform to market," says Chief Technology Officer David Ralin. "LFIRETM's label-free, multiplexed capabilities and inherent simplicity will directly benefit our customers, delivering better results in less time and with lower costs." Target applications for the technology include - but are not limited to - immunoassays in the research and diagnostics markets, cell-based studies, high-throughput pharmaceuticals screening and the established label-free applications in biomolecular interaction analysis.

Chief Engineering Officer Jeffrey Chongsathien M.A. Cantab. adds, "We look forward to creating a robust, flexible and modular product portfolio of laboratory instrumentation and consumables, built on LFIRETM." The initial instrument will be a desktop microplate reader, with a set of 'alpha' evaluation units expected to be completed in the first quarter of 2011 and made available for use by key academic collaborators and strategic industry partners.

Company Founder and CEO William Rassman M.D. noted that the grant will 'jump-start' the commercialization of the product and will be the forerunner of other funding events.

About Maven Biotechnologies

Maven Biotechnologies (www.mavenbiotech.com) is a privately-held biotechnology company located in Pasadena, CA. The company has developed LFIRE™ [pronounced: el - fire] - a flexible, cost-effective, high density imaging technology for the multiplexed, quantitative, label-free, real-time characterization of biomarker binding reactions. The platform addresses applications in biomedical research, drug discovery, immunodiagnostics, biodefense, biological manufacturing and point-of-care. Maven holds 14 granted US and international patents.


'/>"/>
SOURCE Maven Biotechnologies
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU)
2. PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy
3. PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
4. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
5. Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies
6. TriLink BioTechnologies to Sponsor Take Me Out to the Ballgame, a SAY San Diego Event Benefiting San Diego Families in Need
7. Novel Stem Cell Therapy From Cellonis Biotechnologies Can Help Children With Diabetes Get Back Their Normal Lives
8. Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies
9. TriLink BioTechnologies, Inc. Launches New Website and OligoBuilder(R)
10. IMBiotechnologies Receives FDA Clearance to Market Occlusin(R) 500 Biodegradable Microspheres in the U.S.
11. Epeius Biotechnologies Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... JUNCTION, N.J. , Feb. 4, 2016 /PRNewswire/ ... care immunotherapy leader commercializing its flagship CytoSorb® blood ... cardiac surgery patients around the world, announced that ... will present at the Source Capital Group,s 2016 ... and update on the company.  ...
(Date:2/4/2016)... , Feb. 4, 2016 Sinovac Biotech ... a leading provider of biopharmaceutical products in ... of its board of directors received on February 4, ... 2016, from a consortium comprised of PKU V-Ming ( ... Biomedicine Co., Ltd., CICC Qianhai Development ( Shenzhen ...
(Date:2/3/2016)...  Discovery Laboratories, Inc. (NASDAQ: DSCO ), ... surfactant therapies for respiratory diseases, today announced that ... award as a component of employment compensation for ... and Chief Executive Officer.  The award was approved ... 2016 and granted as an inducement material to ...
(Date:2/3/2016)... ... February 03, 2016 , ... Aerocom, a world-leading ... to the North American healthcare market. , Aerocom Healthcare, LLC will be based ... company will provide new pneumatic tube systems or expand existing systems within the ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016 Technology Enhancements Accelerate ... an analysis of the digital and computed radiography markets ... , and Indonesia (TIM). ... and market size, as well as regional market drivers ... and discusses market penetration and market attractiveness, both for ...
(Date:2/2/2016)... 2, 2016  Based on its recent analysis ... recognizes US-based Intelligent Retinal Imaging Systems (IRIS) with ... for New Product Innovation. IRIS, a prominent cloud-based ... America , is poised to set the ... retinopathy market. The IRIS technology presents superior price-performance ...
(Date:2/1/2016)... 2016  Today, the first day of American Heart ... develop a first of its kind workplace health solution ... In the first application of Watson ... ), and Welltok will create a new offering that ... analytics, delivered on Welltok,s health optimization platform. The effort ...
Breaking Biology News(10 mins):